Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

NCT01242514 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
1917
Enrollment
INDUSTRY
Sponsor class

Stopped AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.

Conditions

Interventions

Sponsor

AstraZeneca